Mochida Pharmaceutical (TSE:4534) reported a net profit margin of 5.7%, up from 4.3% a year earlier, with earnings surging 36.5% over the past year. Despite this progress, shares currently trade at ¥3 ...

Mochida Pharmaceutical Co Ltd is a Japan-based company principally engaged in the production and sale of drugs. The Pharmaceutical-related segment is engaged in the manufacture, purchase and sale of ...

Mochida Pharmaceutical Co., Ltd. (JP:4534) has released an update. Mochida Pharmaceutical Co., Ltd. reported a 3.3% increase in net sales for the six months ending September 30, 2024, compared to the ...

Bonjesta ® is a formulation developed by Duchesnay to manage nausea and vomiting of pregnancy (NVP), a common condition affecting more than half of Japanese pregnant women 1) for which there are no ...

(Tokyo, December 13, 2011) Mochida Pharmaceutical Co., Ltd. announces that it has entered into a License Agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, ...

Shire has signed a licensing deal with Mochida Pharmaceutical Co which will see the Tokyo-based firm develop and sell the ulcerative colitis therapy Lialda in Japan. Shire has signed a licensing deal ...

Determining whether Mochida Pharmaceutical—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current ...

Mochida Pharmaceutical Co. Ltd. engages in the research, development, manufacturing and sale of pharmaceuticals, healthcare products, and medical equipment. It operates through following business ...